Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter randomized trial evaluating induction treatment with VIP-reinforced-ABVD (VIP-rABVD) versus CHOP/21 in patients with newly diagnosed peripheral T cell lymphoma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Grenoble
• Collaborator: French Innovative Leukemia Organisation
• Treatments: Doxorubicin; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• newly diagnosed untreated PTCL

• age 18 and 70 years

• performance status ≤ 2

• Ann Arbor stage I to IV

• normal cardiac ventricular ejection fraction over 50%

• normal hepatic function (asat, ALAT, PAL < 2.5 ULN)

Exclusion Criteria:

• cutaneous form of PTCL

• previous treatment

• age < 18 and > 70

• performance status > 2

• abnormal cardiac or hepatic functions

• HIV-, HCV- or HBV- positivity